Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Source :: Legal Monitor Worldwide. June 25, 2024
Publication Year :: 2024
Abstract: (GlobeNewswire) - DarBioscience, Inc.(NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced the publication in Obstetrics & Gynecology, the official publication of the American [...]

Subjects :: United States. Food and Drug Administration
Women -- Health aspects
Sildenafil
Sexual excitement
Biotechnology industry -- Product development
Psychosexual disorders -- Drug therapy
Clinical trials
Obstetrics
Business, international
Law
American College of Obstetricians and Gynecologists

Tools